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ABSTRACT 
 
High-fat diet (HFD)-induced obesity is a risk factor contributing to cardiovascular 
disease. Excessive accumulation of fatty acids in the heart can cause cardiac dysfunction 
and heart failure, and is referred to as lipotoxic cardiomyopathy. A number of 
pathological conditions can create this lipotoxic environment in the heart, such as 
obesity, insulin resistance, and diabetes mellitus. The deleterious effects of 
hyperlipidemia on the heart are well recognized. Many signaling pathways associated 
with cardiac lipotoxicity have been suggested. However, there is limited insight into the 
epigenetic signaling mechanism of the heart in response to excessive fatty acids 
preceding metabolic and vascular disorders, and the associated epigenetic mechanisms 
promote lipotoxic cardiomyopathy. Therefore, the main purpose of this study is to 
delineate the initial epigenetic signaling mechanism in response to lipid overload and 
define its contribution to lipotoxic cardiomyopathy. In our mouse model, we found that 
the animals that have been fed with high fat diet (60% kcal) for 2 weeks are predisposed 
to hemodynamic stress (transverse aortic constriction) with an increase of miR-23a and 
miR-23b expression levels. Also, these 2 miRs target on a histone lysine 36 
methyltransferase called Setd2 and repress its expression, which might cause the 
cardiomyopathy predisposed phenotype. In vivo, we identified the above hypothesis by 
using Setd2 cardiac specific haploinsufficiency mice and Setd2 cardiac-specific 
transgenic mice. In conclusion, we observed that high fat diet caused heart predisposed to 
hypertrophy through upregulation of miR-23a and miR-23b, and repress Setd2. 
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CHAPTER I 
INTRODUCTION 
High-fat diet (HFD)-induced obesity is a risk factor contributing to cardiovascular 
disease. Excessive accumulation of fatty acids in the heart can cause cardiac dysfunction 
and heart failure, and is referred to as lipotoxic cardiomyopathy. A number of 
pathological conditions can create this lipotoxic environment in the heart, such as 
obesity, insulin resistance, and diabetes mellitus. The deleterious effects of 
hyperlipidemia on the heart are well recognized. Many signaling pathways associated 
with cardiac lipotoxicity have been suggested. There is still limited insight into the 
epigenetic signaling mechanism of the heart in response to excessive fatty acids 
preceding metabolic and vascular disorders, and the associated epigenetic mechanisms 
that promote lipotoxic cardiomyopathy. Therefore, the main purpose of the study is to 
delineate the initial epigenetic signaling mechanism in response to lipid overload and 
define its contribution to lipotoxic cardiomyopathy. 
About 60-80% of ATP generation depends on β-oxidation of fatty acids in the adult 
heart. A precise balance of lipid uptake and oxidation is critical for normal cardiac 
function. There is accumulating evidence from both basic research and clinical 
observations showing that an excessive amount of fatty acids in the heart is a deleterious 
factor that impairs cardiac function and structure; this process is called lipotoxic 
cardiomyopathy. Pathological disorders such as obesity, insulin resistance, and diabetes 
mellitus can elicit this lipotoxic environment in the heart. Therefore, a better 
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understanding of the molecular regulation that underlies lipotoxic cardiomyopathy is 
highly important and significant. 
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CHAPTER II                                                                                                                     
HIGH FAT DIET CAUSED MICE HEART PREDISPOSED TO HEMODYNAMIC 
CHALLENGE DUE TO MIR-23 UPREGULATION  
 
Overview of This Part  
 
High-fat diet (HFD)-induced obesity is a risk factor contributing to cardiovascular 
disease1. Excessive accumulation of fatty acids in the heart can cause cardiac 
dysfunction and heart failure, and is referred to as lipotoxic cardiomyopathy. A number 
of pathological conditions can create this lipotoxic environment in the heart, such as 
obesity, insulin resistance, and diabetes mellitus. The deleterious effects of 
hyperlipidemia on the heart are well recognized. Many signaling pathways associated 
with cardiac lipotoxicity have been suggested. However, there is limited insight into the 
epigenetic signaling mechanism of the heart in response to excessive fatty acids 
preceding metabolic and vascular disorders, and the associated epigenetic mechanisms 
promote lipotoxic cardiomyopathy. Therefore, the main purpose of this study is to 
delineate the initial epigenetic signaling mechanism in response to lipid overload and 
define its contribution to lipotoxic cardiomyopathy. In this study, we found that the 
animals fed with high fat diet (60% kcal) for 2 weeks are predisposed to hemodynamic 
stress (transverse aortic constriction) with an increase of miR-23a and miR-23b 
expression levels, In vivo, by using adeno-associate virus, miR-23a and miR-23b 
overexpression in cardiomyocyte are achieved. Mice with miR-23a and/or miR23b 
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overexpression were predisposed to hemodynamic stress, while blocking these two miRs 
by antagomiRs reverse the dilated cardiomyopathy even with the presence of high fat 
diet and TAC. The data strongly suggest that the increase of the two miRs might be 
responsible for HFD-induced cardiaclipotoxicity. 
 
Literature Review 
 
High Fat Diet and Metabolism Change  
Presently, a diet enriched in fat, especially saturated fatty acid, has been largely reported 
to be associated with arthritis, cancer, cardiovascular disease, diabetes, hypertension, 
obesity or stroke1-8. The mechanism behind the pathology changes are the broken 
balance in between fatty acid uptake and utilization. Under physiological conditions, 
lipid taken from diet will be broken down under β-oxidation and release energy in the 
form of ATP to supply the body needs. While under a high fat condition, the lipid supply 
exceeds oxidative capacity, which leads to the imbalance between uptake and oxidation 
of fatty acid, especially during the early exposure of high fat diet when none of the 
metabolism compensation change developed. All the above changes will lead to the 
upregulation of triglyceride level and free fatty acid level in circulation and lipid 
deposition in peripheral organs such as liver, adipose tissue, heart and muscle, which is 
called ectopic fat deposition. Ectopic fat is associated with insulin resistance and type 2 
diabetes mellitus (T2DM). It has been widely accepted for the correlation between fatty 
acid infusion and insulin resistance since 1963 in animal models as well, which indicated 
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that fatty acids impaired insulin-mediated glucose uptake9. Multiple molecular pathways 
are involved, such as Diacylglycerol (DAG) and Novel Protein Kinase C (PKC)s10, 
Ceramides and Akt211,etc.  
 
Lipid Metabolism Balance 
Lipid metabolism is the break down or storage of fats for energy, these fat are obtained 
from consuming food or synthesized by liver. More than 95% of dietary lipids are 
triglycerides (TGs); the rest are free fatty acids (FFAs), cholesterol, phospholipids, and 
fat-soluble vitamins. Dietary triglycerides and cholesterol esters are transported by 
chylomicrons, and in adipose and muscle tissue, apoprotein C-II (apo C-II) on the 
chylomicron activates endothelial lipoprotein lipase (LPL) to convert 90% of 
chylomicron triglycerides to fatty acids and glycerol, which are taken for energy use or 
storage. Due to the hydrophobic nature of lipids, they need to be transported by 
lipoproteins that are synthesized by the liver to the cytoplasm and hydrolyzed into 
glycerol and fatty acids.  Lipoproteins circulate through the blood continuously until the 
TGs that they contain are taken up by peripheral tissues or the lipoproteins themselves 
are cleared by the liver.  
 
Factors that stimulate hepatic lipoprotein synthesis generally lead to elevated plasma 
cholesterol and TG levels, the same time, diet fat overtake has the same effect.  Fatty 
acid can be oxidized into acetyl-coA and produce ATP when demanded. Carnitine acyl 
transferase I limits the speed of fatty acid oxidation. While acetyl-coA can used for 
6 
synthesize fatty acid and energy storage when the amount built up, this is reason that 
take in more calories than body needs leads to lipid deposition. 
Lipid Accumulation and Lipid Toxicity in Heart 
Under physiological conditions, fatty acid can be stored in different types, among which 
triglyceride is the most harmless intracellular lipid storage that consists of a glycerol 
backbone bound with three fatty acids, majority of the triglycerides are stored in 
adipocytes with only minimal lipid accumulation in liver or muscle. While the fatty acid 
uptake and utilization mismatch leads to acetyl-coA, as the central molecular of protein, 
carbohydrate and lipid metabolism, came from the breaking down of the macro 
nutrients, going back toward adipose tissue, cause pathological conditions such as 
insulin resistance, glucose intolerance, leptin increase, adiponectin decrease, etc. Fatty 
acid deposited in the non-adipose tissue, such as kidneys, liver, heart and skeletal 
muscle, will cause the lipotoxicity through the lipid intermediates such as fatty acyl-
CoAs, diacylglycerol and ceramides12.Increased cardiac lipid content has been linked to 
impaired systolic function and increased left ventricular mass13. Recent studies with 
more advanced imaging methods showed increased intramyocardial lipid content in 
patients with non-ischemic heart failure14, which is further exacerbated with obesity15, 
diabetes mellitus14, 15, and metabolic syndrome16. The link between cardiac lipid 
accumulation and metabolic cardiovascular complications, such as diabetes mellitus and 
metabolic syndrome has been reported more than 50 years ago17. The deleterious effects 
7 
of hyperlipidemia on the heart have been widely studied and many pathway associated 
with cardiac lipotoxicity have been suggested18-22. 
Heart Energy Supply under Physiology and Pathological Condition 
Different from other organs in the body that use glucose as their priority energy supply, 
the heart uses fatty acid. Under physiological condition, cardiac metabolism of the adult 
heart primarily depends on fatty acid utilization for oxidative phosphorylation and ATP 
generation18. The physiologic balance of lipid oxidation and uptake prevents excess 
lipids accumulation. Due to the tremendous energy demanding of the heart, oxidation of 
large amounts of fatty acid requires a fully oxygen supply. Nonetheless, under 
pathological conditions such as most forms of heart failure, obesity, diabetes, ischemia, 
sepsis that lead to fatty acid oxidation altered and often also accumulation of lipids. 
Meanwhile the heart switches its major energy supply from lipid toward glucose and 
reduced gene expression involved in fatty acid metabolism with relative increase in 
expression of gene involved in glucose metabolism18. Also the changes accompanied 
with reduced myocardial ATP production of due to less ATP molecules generated form 
glycolysis compared with fatty acid oxidation. Notably, in failing myocardium lipids 
accumulation in subjects with diabetes and obesity with increased levels of toxic 
intermediates leading to more severe lipotoxicity that already been mention above. 
8 
Diabetes and High Fat Diet 
Dietary consumption of fatty acid, exotic fatty acid is the major contributor to breaking 
the balance of fatty acid uptake and oxidation. Plasma free fatty acid levels can be 
reduced by insulin. Consequently, elevations of circulating plasma FFA concentration 
can be prevented if large amounts of insulin can be secreted. If hyperinsulinemia cannot 
be maintained, plasma FFA concentration will not be suppressed normally, and the 
resulting increase in plasma FFA concentration will lead to the compensate increase in 
fatty acid oxidation and acetyl-coA level. Acetyl-coA appears to reduce the activity of 
pyruvate dehydrogenase and result in gluconeogenesis23. Meanwhile these individuals 
are resistant to insulin-stimulated glucose uptake which leads to 
hyperglycemia. Consistent high fat diet will lead to insulin resistance and 
hyperinsulinemia due to the above mechianism24, as well as other pathological changes 
including impaired glucose tolerance (IGT), increased plasma triglyceride concentration, 
and decreased high-density lipoprotein cholesterol concentration, all of which are 
diagnostic standards of type II diabetes and are associated with increased risk for 
cardiovascular diseases (CAD). 
Diabetic Cardiomyopathy 
According to International Diabetes Federation reports in 2015, diabetes might  leads to 
cardiac complications such as cardiac vascular injury, atherosclerotic plaque formation, 
and even myocardial infarction25.Among the above complications, myocardial disorder 
without hypertension or coronary artery disease, named as diabetic cardiomyopathy 
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(DCM), has received much attention in recent years26. DCM has been noticed in both 
human and animal models with Type 1 or Type 2 diabetes27. Diabetic Cardiomyopathy 
is one of those diseases that occurs to the heart muscles in diabetic patients.  
 
Hyperinsulinemia, insulin resistance and hyperglycemia are independent risk factors for 
the development of diabetic cardiomyopathy28. One of the common symptoms noticed is 
systolic dysfunction and its role in symptomatic heart failure, left ventricular dilation and 
atherosclerosis or hypertension. Literature has reported rodent models with chronic 
diabetes present abnormalities in left ventricle diastolic functions with or without 
systolic dysfunction. Also, diastolic dysfunction has been described in patients with 
Type I and Type II diabetes has been recognized as the abnormality of cardiac tissue 
independent from vascular defeat in diabetes29.  
 
Insulin resistance and hyperinsulinemia increase systemic metabolic disorders, activate 
the SNS, activate RAAS, prompt oxidative stress, mitochondrial dysfunction and 
endoplasmic reticulum stress and impair calcium homeostasis. 
 
 Meanwhile the abnormal lipid metabolism accentuates diabetes cardiomyopathy. 
Increased circulating triacylglycerol levels lead to increased fatty acid delivery to 
cardiomyocytes and, thus, enhanced fatty acid β-oxidation and impaired insulin 
metabolic signaling in diabetic hearts30. These effects result in cardiac fibrosis, 
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hypertrophy, cardiomyocyte death, dysfunction of the coronary microcirculation and 
eventually heart failure.  
 
Hypertrophic Cardiomyopathy 
The most common stimuli for cardiac hypertrophy are long-standing hypertension; 
valvular insufficiency and stenosis; myocardial infarction (MI) or ischemia associated 
with coronary artery disease (CAD); congenital malformations; myocarditis due to an 
infectious agent; familial hypertrophic and dilated cardiomyopathies; and diabetic 
cardiomyopathy31, 32. The above stimuli cause the individual cardiomyocytes to grow in 
length and/or width as means of increasing cardiac pump function and decreasing 
ventricular wall tension, this process inducing a state of compensated hypertrophy state, 
while in the long term, myocardial hypertrophy predisposes individuals to arrhythmia, 
heart failure, and even sudden death33, 34. In vivo and in vitro studies have revealed a 
serial signaling pathway and different molecules that are involved in the development of 
cardiac hypertrophy, such as G-protein coupled receptor activation induced protein 
kinase C (PKC) activation35, internal sensory apparatus such as integrin and Z-disc that 
transduce biomechanical stress signals through attached signaling molecules and activate 
downstream small GTPase36, 37, MAPK signaling38, calcineurin–NFAT pathway39, PI3k 
–AKT-mTOR pathway40, Class II HDACs41. Recent studies reported that cardiomyocyte 
growth can lead to concentric hypertrophy(HCM) or eccentric hypertrophy(DCM) based 
on the different tension index(calcium vs time-profile) which the indicating the 
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Ca2+ affility and contractile force of the cardiomyocyte decide the cardiomyocyte growth 
in width (HCM) or length (DCM)42-44.  
 
High Fat Diet Regulation on Micro-RNA Level in Heart 
The biological and pathological functions of microRNAs have been widely recognized 
in many organs including the heart. Intensive studies have focused on the essential role 
of microRNAs in heart development and different cardiac diseases45-47.  Very few 
microRNAs have been identified to be directly associated with lipid-induced cardiac 
toxicity47-49. Recently, two excellent studies have observed the upregulation of miR-195 
and miR-451 in correlation to lipid overload. The responsive increase in the expression 
levels of the two miRs promote cardiomyocyte death and cardiac hypertrophy through 
inhibition of their downstream targets48, 49. The two studies either investigate the 
mechanism in isolated cardiomyocytes or mice that fed with high fat diet for 20 weeks. 
There are also studies that focus on different types of high fat diet caused micro-RNA 
profile change50.  The mechanism underlying early exposure to high fat diet as the cause 
of cardiac micro-RNA profile change remains unknown. Continual discovery of critical 
miRs in response to excessive lipid stress is critically needed to uncover the initial 
signaling that triggers the detrimental cascades into disease and will also close the 
current knowledge gap in lipotoxic cardiomyopathy studies. The purpose of our study is 
to fill this gap. 
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Materials and Methods 
 
Cell Culture and Palmitic Acid Treatment 
Human embryonic kidney epithelial cell line 293T (HEK 293T) was obtained from 
ATCC. Cells were cultured in DMEM with 10% FBS.  
 
Palmitic acid (P0500 Sigma Aldrich) was dissolved in DMSO and added into culture 
medium at final concentration 1µM. For the control group, the same amount of DMSO 
were added. 
 
miR-mimic, miR-inhibitor Used in in vitro Assay 
Overexpression of miR-23a and miR-23b were achieved by transient transfections of 
CMV-miR23a or CMV-miR23b expression vectors. The miRIDIAN microRNA Hairpin 
Inhibitors were used to inhibit micro RNAs in the in vitro assay (GE Healthcare 
Dharmacon, Lafayette, CO). Antago-miR-control: IN-001005-01-20, antago-miR-23b-
3p: IH-310379-07- 0010, antago-miR-23a-3p: IH-300494-05-0010) at the final 
concentration of 100nM.  
 
Generation of Recombinant Adeno-associate Virus 
The recombinant adeno-associated virus used to express miR-23a and miR-23b (Ad-
AAV) was generated by using DNA double strain synthesis (IDT), synthesizing 66-base-
pair miRNA precursors sequence with primers  
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5′-AGTCAGATGTACAGTTATAAGCACAAGAGGACCAG-3′ for mmu-miR-23a 
and 5′-TTATTCAAGATCCCGGGGCTCTTCC-3′ for mmu-miR-23b. The fragment 
was inserted into vector AAV-U6-GFP.  
5′-AGTCAGATGTACAGTTATAAGCACAAGAGGACCAG-3′ was used as a 
control fragment. For adeno-associated virus production, AAV-U6-GFP, AAV-DJ/8 and 
pHelper plasmid (Cell Biolabs) were co-transfected into 293T cells using calcium 
transfection. Virus were harvest after 72 hours through 4 thaw-freeze cycles. Virus title 
was measured by AAV-quick title kit (VPK-145, Cell Biolabs, San Diego, CA). 
 
Gene Transient Transfection 
All gene transient transfections were performed using the NEON transfection system 
(MPK5000; Life Technologies). 293T cells were suspended by the density of 5*10^7 
cells/ml, electroporation parameter was 1100 voltage, 20ms pulse width, 2 pulses, the 
efficiency of transfection is more than 80% under this condition.  
 
Cells were immediately seeded after the electroporation transfection. 
 
High Fat Diet Feeding  
The Institutional Animal Care and Use Committee (IACUC) of Texas A&M University 
Health Science Center Institute of Biosciences and Technology approved the 
experiments with animals. Male mice with C57BL/6 background, at the age of 10 weeks 
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were used, and fed with high fat diet (fat provide 60% Kcal, Research Diet, D12492), the 
control group was fed with normal chow. After feeding for 2 weeks, echocardiography 
was performed to record the cardiac function and molecular markers were checked in 
heart. 
 
Cardiac Function Assessment by Echocardiography 
For cardiovascular function measurements, a Vevo770 High-Resolution Micro-Imaging 
System (VisualSonics, Toronto, ON, Canada) with 30-MHz probe (RMV-707B) was 
used.  
 
Male mice in each group were anesthetized with 3–4% isoflurane, and then switched to 
1–1.5% isoflurane mixed with 100% oxygen. At the level of the papillary muscles, 2-
dimensional guided M-mode echocardiography was obtained from anterior (+septum) 
and posterior walls.  
 
Transverse Aortic Constriction 
Mice are divided into different groups. First group, mice have been fed with 2 weeks of 
high fat diet or normal chow; second group mice been injected with the adeno-associate 
virus specifically expressing miR-23a or miR-23b in cardiomyocyte; third group mice 
have been injected with antagomiR and fed with high fat diet for 2 weeks. Those mice 
are anesthetized with 3% isoflurane with 100% oxygen, the thymus was retracted to 
expose the transverse aorta. Between the right innominate and left carotid artery, an 
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aortic constriction was achieved by tying a 6-0 suture against a 3 mm length of 27 gauge 
needle. After two knots, the 27 gauge needle was promptly removed, which yielded a 
constriction of ∼0.3 mm as the outer diameter of the 27 gauge needle. The procedure 
imposed a 60–80% aortic constriction on the animal. To minimize the variation of the 
constriction among the animals, only the mice with a ratio of right-to-left carotid artery 
flow velocity from 5 : 1 to 10 : 1 were used. The artery flow velocity was measured by a 
Pulsed Doppler (Indus Instruments, Houston, TX, USA). As a control, a sham operation 
without occlusion was performed on age-matched littermate mice.  
 
Hematoxylin and Eosin Staining, Immunostaining  
Mice hearts were perfused and fixed by Langendorff Perfusion System (Radnoti, 
120108). The whole heart paraffin sections were applied to Hematoxylin and Eosin 
Staining (51275, Fluka; HT110132-1L, Sigma-Aldrich) and images were captured under 
1.25X magnification with Leica DM2000 histology microscope.  
 
Paraffin sections of the whole heart were used for hematoxylin & eosin, wheat germ 
agglutinin (WGA) (W11262, Thermo Fisher Scientific, NY, USA), Pictures were taken 
under the 40x microscope objective. A total of 20 staining pictures from each group 
were quantified by Leica Application Suite Imaging Software (Version 4.0, Germany). 
Nuclei were visualized by DAPI staining. The images were acquired by fluorescence 
microscopy. 
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Wheat Germ Agglutinin Staining 
Paraffin sections of the whole heart were used for Wheat Germ Agglutinin (WGA) 
Staining. The tissue sessions were deparaffinized and incubated with Wheat Germ 
Agglutinin (Vector Laboratories, Burlingame, CA) at approximately 20 µg/ml in PBS to 
the sections and incubated for 30 minutes at room temperature. The tissue sessions were 
wash with TPBS (PBS + 0.05% Tween™ 20) for 3 times. Nuclei were visualized by 1 
µg/ml DAPI staining for 5 min. Images were captured under the 40x microscope 
objective with Leica DM2000 histology microscope. One image was from the top of the 
interventricular septum and four images were from the left ventricle wall. A total of 20 
staining pictures from each mouse were quantified by Leica Application Suite Imaging 
Software (Version 4.0, Germany). 
Micro-RNA Sequencing Assay and RNA Sequencing Assay 
Total RNA was isolated from the hearts of 10-wk-old mice using miRNeasy kit 
(QIAGEN, Cat No./ID: 217004), and 3 µg was used for RNA-seq or miR-seq. The 
assessment was performed using the Qiagen RT2 Profile PCR Array. 
Data analyses were performed with R (www.r-project.org), a publicly available 
statistical tool for data analysis. Signaling pathway analysis was performed with 
Ingenuity (www.ingenuity.com). 
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Retro-Orbital Sinus Injection 
----[[[[Using a 28-gauge insulin syringe and inserting the needle into the retro-bulbar 
space, mice were anesthetized with 0.2ml 2.5% avertin during the procedure. A maximal 
150ul volume can be injected. Mice were infected with 1 × 1012 Geno Copy of virus by 
injection into the retro-orbital sinus. For antagomiR treatment experiments, mice started 
with high fat diet received a shot of antagomiR through retro-orbital sinus of 80mg/kg 
body weight. A drop of ophthalmic anesthetic (0.5% proparacaine hydrochloride 
ophthalmic solution, Alcon Laboratories, Inc., Fort Worth, TX) was applied on the eye 
after receiving the injection. 
 
Adult Mouse Cardiomyocyte Isolation and Culture 
Adult mouse cardiomyocytes were isolated using the isolation kit (Cellutron Life 
Technologies). Mouse cardiomyocytes were isolated from 10- to 15-week-old adult male 
mice by enzymatic digestion with the Langendorff perfusion system (120108, Radnoti, 
CA, USA) following the Cellutron protocol. The cells were collected by centrifuging at 
1000 rmp for 1 min and cultured onto laminin-coated dishes with AW medium for later 
experiments. 
 
RNA Isolation and qRT-PCR (Quantitative Polymerase Chain Reaction) Analysis 
Isolation of total RNA from mouse heart was performed using TRIzol reagent (Life 
Technologies). cDNAs were synthesized from 1 μg total RNA with the qScript One-Step 
RT-qPCR kit (Quanta Biosciences).  Quantitative RT-PCR was performed using SYBR 
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Green PCR Master Mix (Life Technologies) in the StepOnePlus Real-Time PCR System 
according to the manufacturer’s instructions. 
 
Transcripts were quantified by quantitative PCR (qPCR) analysis. Total RNA was 
prepared by miRNeasy kit (QIAGEN, Cat No./ID: 217004), 0.5ug RNA was used for 
reverse transcription(QUANTA, 95048).  
 
miR-23a and miR-23b transcription were quantified by quantitative PCR (qPCR) 
analysis. Total RNA was prepared by miRNeasy kit (QIAGEN, Cat No./ID: 217004); 10 
ng RNA was used for reverse transcription by TaqMan™ Advanced miRNA cDNA 
Synthesis Kit (Thomas Fisher, A28007,Waltham, MA). Probes for target miRs were 
purchased from Thomas Fisher scientific Waltham, MA (hsa-miR-23a-3p: 478532; hsa-
miR-23b-3p: 477991; hsa-miR-191-5p: 477952). miR-191-5p expression level was used 
for qPCR normalization. Expression levels were determined by the 2−ΔΔCt threshold 
cycle method. 
 
Statistical Analysis  
Data are presented as means ± s.d. Unpaired, two-tailed student’s t test was used for two 
group comparisons. One-way ANOVA followed by Student-Newman-Keuls test was 
used for multiple group comparisons.  
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All statistical analyses were performed in software SigmaPlot 11.0 (Systat, San Jose, CA, 
USA). The P value < 0.05 was considered as significant difference. 
Results of This Part 
Short-Term (2-Week) HFD is a Detrimental Factor that Exacerbates Cardiac 
Dysfunction and Hypertrophy after Hemodynamic Challenge 
In this mouse model after 2 weeks feeding of high fat diet, there was no significant 
change in cardiac function or morphology in the mouse heart from the high fat diet 
(HFD) group (Fig.1 Sham) compared with mice fed with normal diet (ND). After the 
diet treatment followed by 3 weeks transverse aortic constriction (TAC), mice in the 
HFD group developed dilated cardiomyopathy with significantly enlarged 
cardiomyocytes and worsened cardiac function compare to the normal diet (ND) group. 
(Fig.1 TAC) 
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Figure. 1. Short-term (2-week) HFD is a detrimental factor that exacerbates cardiac 
function and promotes hypertrophy. (A). H&E staining for mouse myocardial section. 
Scale bar: 1 mm. (B). Wheat germ agglutinin (WGA) staining exhibits significant 
increase in cardiomyocyte size in HFD heart after 3-week TAC. Scale bar: 10 μm. (C). 
Quantification of the cardiomyocytes size. (D). Cardiac function assessments show that 
HFD mice develop heart failure after TAC. TAC: transverse aortic constriction; ND: 
normal diet; HFD: high fat diet..  * P<0.05, n=5. 
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2-week HFD Induces Profound Increases in miR-23a and miR-23b in Mouse Heart 
To rule out the pathways that are involved in the development of the above phenotype, 
miR-seq was performed on the high fat diet fed 2-week mouse heart. The result indicated 
that there are over 100 microRNA expression levels are increased in the 2-week HFD 
mouse heart and, within those miRs, miR-23a and miR-23b are specifically enriched in 
the heart. Quantitative PCR was used to further confirm this result and found that after 
feeding with HFD for 2 weeks, miR-23a and miR-23b increased 18.37- and 12.82-fold 
compared to the normal chow fed mouse heart. To exclude the effect of TAC in the 
development of the predisposed cardiac hypertrophy phenotype that happens in high fat 
diet fed heart, miR-23a and miR-23b levels in the TAC heart compare with the heart 
from Sham group were checked, the result indicated that TAC itself can only induce a 
slight increase on these 2 miRs, 0.35-fold increase of miR-23a and 0.78-fold increase of 
miR-23b. (Fig.2) 
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Figure. 2. 2-week HFD induces profound increases in miR-23a and miR-23b in mouse 
heart. The levels of two miRs are quantified by qPCR. A moderate increase in miR-23b 
is also detected in 3-week TAC mouse heart. *P<0.05, n=5. 
 
Upregulation of miR-23a and miR-23b are Responsible for HFD Induced Lipotoxic 
Cardiomyopathy 
To further investigate whether the upregulation of these 2 miRs caused predisposition to 
TAC, forced expression of miR-23a and miR-23b separately or jointly in mouse heart 
were achieved by the adeno-associate virus system, which successfully boosted the 
expression level 1.7-fold (Fig.3a) in heart when treated with mice with the AAV 
DJ/8:miR-23a or AAV DJ/8:miR-23b. Co-expression of these 2 miRs did not cause 
redundancy. The mice are viable and normal under physilogical conditions. Similar to 
the 2-week high fat diet fed mice, mice injected with AAV DJ/8:miR-23a or AAV 
DJ/8:miR-23b showed severe cardiac dysfunction compared with the control 
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mice(Fig.3). The cardiac morphology indicated a thicker left ventricular wall and  
developed more severe cardiac hypertrophy (Fig.4a) with enlarged cardiomyocyte size 
(Fig.4 b&c), as compared to the control mice after 3 weeks of TAC.  
 
 
Figure. 3. Overexpression of miR-23 exacerbates cardiac function after TAC.  (A).The 
increase in miR-23 expression in mouse heart is achieved by intravenous delivery of 
adeno-associate virus (AAV) expressing miR-23. The qPCR analysis was conducted two 
weeks after the virus injection (B). AAV-miR-23-treated mice showed deleterious 
cardiac function compared to control mice in response to 3weeks of TAC. * P<0.05, 
n=5. 
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Figure. 4. Overexpression of miR-23 exacerbates cardiac hypertrophy after TAC.  (A). 
H&E staining of mouse heart sections after different adeno-associate virus infection 
which specifically expresses miR-23a and /or miR-23b in cardiomyocyte and 3-week 
TAC. Scale bar represents 1mm. (B). Wheat germ agglutinin (WGA) staining exhibits 
significantly enlarged cardiomyocytes from the AAV-miR-23 treated mouse heart after 3-
week TAC compared with the control hearts. Scale bar: 10 μm. (C). Quantification of 
cardiomyocyte size. * P<0.05, n=5.  
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Blocking miR-23a and /or miR-23b will Rescue Dilated Cardiomyopathy Triggered by 
High Fat Diet and TAC 
 Since the gain-of function experiment achieved a similar phenotype as that observed in 
high fat diet fed mice after 3 weeks of TAC, loss of function experiments were also 
performed to investigate whether miR-23a and miR-23b is not only necessary but 
sufficient to cause the cardiomyopathy phenotype. On day 0, C57BL/6 mice were 
injected with antagomiR (23a, 23b or 23a and b, ctrl) and started being fed with high fat 
diet; 2 weeks after the injection of antagomiR, significant downregulation of miR-23a 
and miR-23b in mice hearts were observed in the antagomiR group (mir-23a, miR-23b, 
miR-23a&b) compared with the control mice (Fig.5a). Then followed  by 3 weeks of 
TAC, the  antagomiR group mice have significantly preserved cardiac function (Fig.5 b) 
and  showed less severe cardiac hypertrophy(Fig.6 a-c). 
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Figure. 5. Repression of miR-23 partially rescue cardiac dysfunction after HFD+TAC.  
(A). Repression of miR-23 expression in mouse heart is achieved by intravenous 
delivery of Antago-miR-23. The qPCR analysis is conducted two weeks after the agents 
injection. (B). Antago-miR-23-treated mice showed preserved cardiac function 
compared to control mice in response to 3 weeks of TAC. * P<0.05, n=5.  
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Figure. 6. Repression of miR-23 partially rescued cardiac hypertrophy after HFD+TAC.  
(A). H&E staining for mouse heart sections after HFD2W+TAC3W. Scale bar: 1mm. 
(B). Representative image Wheat germ agglutinin (WGA) staining exhibits resistance of 
cardiomyocytes enlargement from the Antago-miR-23 treated mouse heart after 3-week 
TAC compared to control heart. Scale bar: 10 μm. (C). Quantification of cardiomyocyte 
size. * P<0.05, n=5. 
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miR-23a and miR-23b are High Fat Sensors 
 
Based on our observation earlier in this study, miR-23a and miR-23b were significantly 
upregulated under a short-term high fat diet (HFD) in vivo and a 24-hour Palmitic Acid 
(PA) treatment in vitro. To investigate the dynamic change of miR-23a and miR-23b 
levels in response to high fat diet/ palmitic acid, 293T cells have been treated with 
palmitic acid for 24 hours; then upon retracting the treatment, miR-23a and miR-23b 
levels were monitored at 4 hrs, 8 hrs, 12 hrs, 24hrs, 48 hrs after the retraction. In vivo, 
c57bl/6 mice at 10-12 weeks were fed with high fat diet for 2 weeks then switched back 
to normal chow. miR-23a and miR-23b expression levels were monitored after 1 day, 3 
day, 7day and 14 days after the diet switch. The dynamic change of miR-23a and miR-
23b expression levels were observed both in vivo and in vitro, in which the expression 
levels of these two miRs were boosted by high fat diet or palmitic acid treatment, while 
slowly returning to the baseline after the HFD treatment was retracted. (Fig.7) 
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Figure. 7. miR-23a and miR23b are lipid sensors. (A). Excessive fatty acids triggered an 
upregulation of the miR-23a and miR23b and the increase of the two miRs recede upon 
fatty acid withdrawal in 48 hrs in 293 T cell. (B). Mice fed with high fat diet for 2 weeks 
were observed with significant upregulation of miR-23a and miR-23b in hearts, and the 
increase of the two miRs receded after high fat diet was withdrawn in 4 weeks, , n=2.  
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Discussion  of This Part
High Fat Diet in Cardiovascular Disease 
High fat diet is enriched with saturated fatty acid that more easily causes the imbalance 
of fatty acid intake and oxidation compared to normal diet51. Lipid overload-induced 
cell/organ dysfunction, referred to as lipotoxicity, was first reported in Roger Unger’s 
seminal paper in 199452.  
An elevated level of plasma free fatty acids was sufficient to cause β-cell dysfunction in 
the Zucker diabetic fatty rat, which resulted in insulin resistance before non-insulin-
dependent diabetes mellitus. Since then, lipotoxicity has been widely recognized in 
animal models and human diseases including lipotoxic cardiomyopathy14, 18-20, 53-55. 
Lipotoxic cardiomyopathy is closely associated with many long-term chronic metabolic 
syndromes such as obesity, insulin resistance, and diabetes mellitus18-20, 54, 56. Prolonged 
high levels of circulating fatty acids and triglycerides, which commonly exist in these 
metabolic syndromes, will affect the cardiac metabolism by changing from using fatty 
acid into glucose, which further leads to the increase of toxic products such as 
Diacylglycerols (DAGs), ceramides, medium chain acyl carnitines57 that cause cardiac 
dysfunction and injury. 
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Thus, new therapeutic strategies aimed at reducing cardiac and circulation lipid 
accumulation will be a primary approach to prevent lipotoxic heart disease. 
Because of the complexity of the disease, the initial molecular signaling that triggers 
cardiac lipotoxicity preceding metabolic syndromes is relatively understudied and 
remains a challenge in the field. 
Therefore, the majority of the studies on cardiac lipotoxicity have been closely 
associated with diabetic and obesity cardiomyopathy investigations due to their natural 
connection and overlap. 
Cardiac Lipotoxicity 
Given the importance of excessive fatty acid-induced cardiac complication, many 
signaling pathways have been found to be activated by lipid accumulation and have been 
linked to this cardiac toxicity18-22, 55, 56, such as  lipid overload-induced endoplasmic 
reticulum (ER) stress, and ER stress-induced mitochondria dysfunction and cell death; 
mitochondria dysfunction, and mitochondria-mediated apoptosis; excessive generation 
of ROS; lipid metabolic intermediates: generation and accumulation of diacylglycerol 
(DAG), ceramide and acyl carnitines; Altered AMP-activated protein kinase (AMPK) 
signaling; Altered circulating factors such as adipokines; Autophagy activation; 
Inflammatory response; Activation of mitogen-activated protein kinases; Altered PPAR 
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signaling; P53, PKC, PKB, FOXO signaling pathways. All above are the current 
paradigm of excessive lipid-induced cardiac toxicity. 
Epigenetic Regulation in Gene Expression 
The term of epigenetic is emerged in the 1990s, which refers to changes in chromosome 
without alteration in the DNA sequence. Epigenetic modifiers include 1) non-coding 
RNA such as microRNA (miR) and long non-coding RNA (lnc RNA), 2) histone 
modification such as acetylation, methylation etc. 3) DNA methylation and 4) chromatin 
remolding such as chromatin opening and closing. Epigenetic processes are essential for 
development and differentiation, but they can also arise in mature humans and mice, 
either by random change or under the influence of the environment58. Non-coding RNAs 
especially small RNAs are well- known as repressors in all known animal and plant 
genomes59, which mediates translational blocking and mRNA degradation. Histone 
acetyl transferase and histone deacetylase were first described in 1996 with gene 
expression regulator functions60, 61; other than acetylation, histone lysine residue 
methylation status also mediates transcription activities. Histone lysine methylation can 
either be activating such as H3K4 methylation or repressive such as H3K9 tri-
methylation. DNA methylation is initiated by DNA methyltransferases DNMT3A and 
DNMT3B, and are maintained by DNMT162, which will further recruit the methyl-CpG 
–binding proteins (MeCP2) and histone deacetylase complex and lead to histone
deacetylation and gene silencing63, 64. This provides the first molecular evidence linking 
DNA methylation and histone deacetylation with transcription repression. Meanwhile, 
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Tamaru et.al also found that the methylation status of Histone 3 controls DNA 
methylation which further controls downstream gene expression65, and indicating that 
the above 4 categories of epigenetic regulations are not functional parallel while they 
may form a network and regulate each other in different layers.  
 
Above all the epigenetic modifiers, our group was first sequencing the micro-RNA in 
mouse heart that has been fed with high fat diet for 2 weeks for the purpose to 
investigate whether the changes in Micro RNAs affected by high fat diet will contribute 
to the development of cardiac lipotoxicity. Micro RNA are single-strand noncoding 
RNAs that function by binding to miRNA-inducing silencing complex (RISC) to 
generate the mature miRNA, which represses the expression of fully or partially 
complementary target mRNAs66. With micro-RNA sequencing indicating that miR-23a 
and miR-23b significantly upregulated and further verified by quantitative-PCR, and 
further investigation indicating that  the 2 miRs are function as lipid sensor and later 
manipulate gene expression as epigenetic regulators. 
 
Micro-RNA in High Fat Induced Cardiac Pathological Disorders 
In recent years, microRNAs and epigenetics have emerged as important mechanistic 
factors that regulate many pathological disorders. A numbers of studies have shown that 
high fat diet in the long run is associated with cardiac contractile dysfunction and 
remolding due to the increase of toxic lipid intermediates67-71. The significance of 
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epigenetic factors in lipid accumulation-induced cardiomyopathy is undervalued; 
there is limited study that connects exceeding fat accumulation predisposes the heart 
towards cardiac hypertrophy with either micro RNA or histone modifier. Recently, 
microRNA has been broadly reported to be related to multiple disease development such 
as cancer72-74, cardiovascular disease75-79, nervous system disorder80, 81, digestion 
disorder82, 83, obesity84, 85, etc. Very few microRNAs have been identified that 
directly associate with lipid-induced cardiac toxicity47-49, and the limited studies 
either used isolated cardiomyocyte or applied high fat diet to mice for 20 weeks. 
Therefore, in heart, the miRs early signature profiles in response to lipid accumulation 
preceding metabolic disorders remains largely unknown. Continual discovery of miRs in 
response to lipid stress is critically needed to fill the current knowledge gap.  
 
miR-23 in Cardiac Hypertrophy and Heart Failure 
Presently, very limited knowledge of the biological functions of miR-23a and miR-23b 
in the heart 86-88. In humans, a lower myocardial expression level of miR-23a in heart 
failure patients was suggested to correlate with a better recovery of left ventricular 
function89. The elevated circulating miR-23a was detected in acute myocardial infarction 
as well as unstable angina pectoris patients90, and its plasma levels were correlated with 
the degree of coronary stenosis91.  
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In animals, mechanical stretch by TAC and activation of calcineurin can increase miR-
23a and miR-23b expressions in the mouse heart87, 88. Our group confirmed the 
observation and showed that TAC led to a moderate (<1-fold) increase in the two miRs. 
We detected a 17- and 12-fold increase in miR-23a and miR-23b, respectively, in HFD 
mouse hearts, suggesting that HFD is a strong inducer of the expression of the two miRs. 
Furthermore, we found that overexpression of miR-23a and /or miR-23b in mice 
sensitized the animal heart to hemodynamic challenge, and the mice developed 
hypertrophy and heart failure, which indicates that the responsive upregulation of the 
two miRs is a detrimental factor causing exacerbated cardiac lipotoxicity in animals.  
Regarding miR-23 downstream targets, two factors were identified by others: muscle 
specific ring finger protein 1 (MuRF1, also called TRIM63) and forkhead box O3 
(Foxo3)86, 92. The studies reported that the upregulation of miR-23a inhibited the 
expression of MuRF1 and Foxo3, leading to cardiac hypertrophy86, 92. Although, we did 
not observe any significant decreases of MuRF1 and Foxo3 expression in our HFD 
mouse model, indicating a possible different mechanism and target by miR-23 under 
lipid overload conditions. 
 
Manipulation of microRNAs has been demonstrated as a promising and attractive 
therapeutic strategy93, 94. Since there is no study about the biological functions of miR-
23a and miR-23b in cardiac lipotoxicity, our discovery is novel and has translational 
significance for the diagnosis and treatment of cardiac lipotoxicity. Both miR-23a and 
miR-23b can be unique and specific targets for microRNA-mediated therapy for cardiac 
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lipotoxicity. This concept is in line with one recent report showing a responsive 
elevation of miR-23b in the mouse liver after HFD95.Meanwhile, the two miRs are 
highly sensitive to hyperlipidemia, and can serve as biomarkers for dyslipidemia-
mediated organ dysfunction. 
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CHAPTER III                                                                                                           
DECREASED EXPRESSION LEVEL OF SETD2 IS RESPONSIBLE FOR MIR-23A 
AND/OR MIR-23B-MEDIATED LIPOTOXIC CARDIOMYOPATHY 
 
Introduction and Literature Review 
 
Epigenetic Regulation in Cardiac Hypertrophy 
Epigenetics indicates of a DNA sequence-independent genome functions regulated 
pattern. In recent years, many epigenetic markers have been discovered on nuclear 
histones which function as fine tuners for DNA exposure and read-out, among them 
including acetylation, methylation and phosphorylation96. Epigenetic mechanisms 
control chromatin structure through histone modifications and DNA methylation. The 
major modifications are acetylation and deacetylation on specific lysine residues of 
histone, which are operated by Histone acetyltransferases (HATs) and histone 
deacetylases (HDACs). Histone acetylation opens and activates chromatin, while 
deacetylation of histones and DNA methylation compact chromatin making it 
transcriptionally silent. Both can activate or repress gene transcription. New evidences 
shows that HDACs function in the regulation of lipid and other metabolic pathways will 
open new perspectives to the pathophysiology of metabolic disorders97. Environmental 
influence on Epigenetic modifications have produced a special interest in finding the 
cardiac hypertrophy origin. Within multiple epigenetic modifications, methylation of 
lysine residues on the histoneH3 and H4 N- terminal tails are responsible for controlling 
 38 
 
 
gene expression98-100. Therefore, the balance of histone lysine residues 
methylation/demethylation is important for genomic integration and gene expression101, 
102. Both the localization and the degree of methylation (mono-, di-, or tri-methylation) 
of the histone lysine residues affect differential gene expression102-104. Evidence 
suggests that loss of regulation of these lysine methylation properties could lead to 
promoting congenital heart diseases and cardiac hypertrophy in adulthood105, 106. 
Different from the established role of histone modifiers and HDACs in heart failure 
transcriptional regulation107, 108, relatively little is known about DNA methylation in 
cardiac hypertrophy. Recent data suggested DNA methylation can respond to external 
stimuli and correlates with the cardiomyocyte functional state in cardiovascular 
disease109, 110. Stenzig et al. show beneficial effects of non-nucleosidic DNMT 
inhibitors on cardiomyocyte contractile function111. Thus, in contrast to the above-
described epigenetic mechanisms that modulate gene expression at the transcription 
level, miRNAs control gene expression at the post-transcriptional level. Each miRNA 
might regulate the expression of hundreds of target mRNAs. miRNA genes are 
organized within the genome in the host (protein-coding or non-coding) genes introns 
of or in host exons, as well as intergenic regions as independent genes112. miRNAs 
interact with RNA-induced silencing complex (RISC). RISCs bind to the 3′- UTR 
(untranslated region) of specific mRNA targets. Either translation is blocked or the 
mRNAs are degraded113. A shift toward a fetal miRNA transcription pattern is 
responsible for part of the cardiac proteome modifications during hypertrophy and 
failure113. Genome-wide association study has shed light on the miRs expression pattern 
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change in hypertrophy heart, while the mechanisms under those miRs changes are still 
largely unknown. 
Study of Micro-RNA in Heart 
The biological and pathological functions of microRNAs have been widely recognized 
in many organs including the heart. Intensive studies have focused on the essential role 
of microRNAs in heart development and different cardiac diseases45-47, 114. A number of 
studies have indicated miRNA expression signatures of human hearts115-117 and mouse 
hearts87, 88, 118-120 and have demonstrated miRNA arrays that are mis-expressed, either 
positively and/or negatively, in cardiac disease. Meanwhile, the researchers have found 
that a shift toward a fetal miRNA transcriptome is responsible for at least part of the 
cardiac proteome modifications occurring with cardiac hypertrophy and heart failure. 
Genome-wide miRNA expression profiling study provided evidence that miRNAs 
signatures of three human heart pathologies— dilated cardiomyopathy, ischemic 
cardiomyopathy and aortic stenosis— are distinct; 43 out of 87 examined miRNAs are 
differentially expressed in at least one of these disease groups115. A following study also 
demonstrated commonalities and differences in 33 miRNAs expression in ischemic 
cardiomyopathy and agnogenic dilated cardiomyopathy117.  
The factors that affect cardiac miRNA transcription are still incompletely understood, 
but it could be conjectured that different miRNA expressions could be clinically 
important for many cardiovascular pathologies if used for diagnostic and/or prognostic 
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purposes115. Applied with combination of mRNA profiling, miRNA transcriptome was 
indicated to be a delicately perceptive biomarker of severe heart failure121. 
Except for pathogenesis and etiology, the progression of disease is another significant 
aspect of cardiovascular disease; more than half of patients with cardiomyopathy 
progress unyieldingly towards heart failure and death. While the causes of such 
progression are not well investigated, the miRNA transcriptomes study could uncover 
major features of this process. For sure, studies using mouse models are providing 
evidence that the miRNA is dynamically regulated, not only in the process of ageing120 
but also in the progression of myocardial infarction, hypertrophy and heart failure88, 118-
120, 122. Differences between the miRNA transcriptome in hypertrophy with that in heart 
failure might have been partly documented in patient samples115. 
During disease progression, the miRNA transcriptome alterations could be reversible at 
certain points: Matkovitch et.al have provided evidence that upon biomechanical support 
treatment, miRNA transcription level in heart-failure samples goes back to normal, even 
if this was not reflected by mRNA profile normalization121. Therefore, it seems that 
miRNAs are more sensitive to acute alterations in pathophysiological status than mRNA 
121. Some miRNAs have been found more commonly dysregulated than others in heart 
disease patients, including miR-133, miR-1, miR-30 and miR-150 are often 
downregulated;—and miR-23a, miR-125, miR-195, miR-21, miR-199 and miR-214 are 
often upregulated. Although grouping data from different diseases, models, stages and 
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analysis methods should be performed cautiously, it might be speculated that some 
miRNAs represent 'core mediator' miRNAs that have central causative roles in the 
pathogenesis of heart disorders. Some of these miRNAs have been tested in model 
systems to see whether or not their misexpression is sufficient to produce an effect on 
phenotype (usually heart size). For example, miR-23a, miR-23b, miR-24, miR-195 and 
miR-214 (found upregulated with disease) provoked increased cell size when transfected 
in neonatal cardiac myocytes, and miR-195 was sufficient to provoke pathological 
cardiac growth and dilated cardiomyopathy when overexpressed in transgenic mice87. 
Similarly, inhibition of miR-133, an miRNA found downregulated in human 
hypertrophic cardiomyopathy, was sufficient to induce hypertrophy in wild-type mice123. 
Databases are being developed to provide comprehensive lists of the dysregulated 
miRNAs found in various diseases and models, including those of the heart 123. 
miR-133, together with miR-1, is particularly interesting as a 'key' miRNA for 
hypertrophy, whose expression level has been found reduced in animal models of 
hypertrophy induced either by pathologic (surgically-induced pressure overload) or 
physiologic (Akt overexpression or exercise) stresses124. Although it might not be 
surprising that both miR-1 and miR-133, as they are central to cardiac biology, are found 
altered with hypertrophy regardless of its underlying cause, it does raise question of 
whether and how miRNA dysregulation differs between heart growth induced by 
pathological and physiological means. It might be speculated that miRNAs that are mis-
expressed differentially upon pathologic hypertrophy, when compared with physiologic 
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hypertrophy, have a causative role in the cardiac dysfunction associated with 
unfavorable cardiac remodeling. Future studies should focus on testing such hypotheses. 
Meanwhile, investigating the miRNA profiles differences between inherited cardiac 
diseases and the acquired forms with similarities might also reveal specific miRNAs that 
have a causative role in disease development, which might be used as diagnostic or 
therapeutic agents in pre-clinic medicine. 
 
The target of miRNAs involved in the development of different diseases, such as the two 
muscle-specific miRNAs, miR-1 and miR-133, target at least two transcription factors: 
Hand2 and SRF during cardiogenesis125. Hand2 and SRF further cooperate in the re-
induction of an embryonic pattern of protein expression126, that provoke heart growth 
through hypertrophy. As well, miR-1 target at RASA1, Cdk9, and Rheb, which involved 
in cell growth, and fibronectin, which is an extracellular matrix protein88. Also, miR-
1 has been reported to target at calmodulin and Mef2a that are Ca2+-signaling pathway 
components; when miR-1be repressed with disease, calmodulin and Mef2a were boosted 
and resulted in stimulation of prohypertrophic genes127.miR-133a-1/2 double knockout 
mice show thin-walled hearts and septal defects, and mice surviving to adulthood 
presented dilated cardiomyopathy128. miR-133 has been reported as targeting small 
GTPase RhoA and Cdc42, also WHSC2, which are involve in cardiac genesis and 
induces fetal gene program in cardiomyocytes124. The above 2 studies documented that 
miR-133 has a key role in myocardial development, hypertrophy and cardiac function, 
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while the complexity of miR-133 regulatory mechanism is still underlined, which needs 
to be further elucidated. 
 
The miR-29 family of miRNAs, in particular, has been linked to fibrosis122, which is the 
major feature of abnormal myocardial. A large number of extracellular-matrix-related 
genes were found to be targets of miR-29, including ELN, FBN1, COL1A1, COL1A2 
and COL3A1. miR-29 is downregulated by TGF-β in myofibroblasts, which indicate that 
miR-29 is a negative regulator of matrix-related genes, and its repression is involved in 
the increased collagen deposition during pathological remodeling and progression to 
heart failure. miR-30c and miR-133 which are highly expressed in the heart have also 
been reported as being implicated in cardiac fibrosis129 and target at CTGF, which 
becomes upregulated with heart disease and contributes to myocardial remodeling 
through increased collagen deposition. Another study documented that miR-21is 
upregulated in heart failure cardiac fibroblast and increasing MAPK signaling by 
repressing SPRY1, which might be responsible for fibroblast survival that is independent 
from cardiomyocyte loss130. miR-21 has also been reported as being implicated in 
cardiomyocyte death whose expression is upregulated in cardiac myocytes in response to 
H2O2 treatment, and protecting against H2O2-mediated cell death though targeting at 
PDCD4131. Together with miR-1 and miR-24, miR-21 is upregulated after ischemic 
preconditioning, functioning as cardiac a protector by upregulating eNOS, HSP70, and 
HSF1132. Other than being involved in the hypertrophic progress, miR-1and miR-
133 have been reported to be involved in the regulation of cell death133. Overexpression 
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of miR-1 provokes apoptotic cell death in H2c9 cells, whereas miR-133 protects against 
H2O2-induced apoptosis
133 through targets HSP60 and HSP70 for miR-1, 
and CASP9 for miR-133. Meanwhile, miR-1 is boosted in ischemic cardiomyopathy and 
myocardium with coronary artery disease, which might contribute to the cardiac 
apoptosis under these conditions. 
Under pathological conditions, increased myocardial mass might not be paired with 
appropriate angiogenesis that is associated with normal growth patterns, as pointed out 
two decades ago134. miR-130a, miR-17-92 cluster and miR-378 
target MEOX2 and/or HOXA5, THBS1 and/or CTGF, and Sufu135, 136 have been 
identified as proangiogenic miRNAs. Meanwhile, miR-221 and miR-222 by targeting c-
kit and regulating eNOS indirectly inhibit endothelial cell migration, proliferation and 
angiogenesis137. Also numbers of miRNAs with predicted angiogenic related targets are 
upregulated in rat myocardial endothelial cells with type 2 diabetes and lead to impaired 
angiogenesis such as miR-320 target at Flk1, VEGFc, IGF-1, IGF-1R and FGF, 
documented as important angiogenic miR; miR-126, has been shown to negatively 
regulate VEGF in endothelial cells after myocardial infarction through 
SPRED1 and PIK3R2138, 139. 
One of the well-studied miRNAs linked to cardiac pathology is miR-208, which is 
encoded within an α-MHC gene intron and controls the β-MHC expression in response 
to cardiac stress140. This miRNA has been found upregulated with hypertrophy and heart 
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failure. miR-208-null mice that underwent pressure overload or pathological remodeling 
did not experience that hypertrophic or fibrotic processes that respond to stress. 
THRAP1, co-regulator of the thyroid hormone receptor was identified as miR-208 
target, which is upregulated in the absence of miR-208, results in increased protein 
actions on the hormone response elements which will consequently repressed β-MHC 
promoter. Thus, miR-208 postnatally regulates α-MHC expression as an on–off 
switch116, 119.  
Although, the early signature profiles of miRs in response to lipid accumulation in the 
heart preceding metabolic disorders or cardiac remodeling (hypertrophy) remains largely 
unknown. Continual discovery of critical miRs in response to excessive lipid stress is 
crucially needed to uncover the initial signaling that triggers the detrimental cascades 
into disease; and will also close the current knowledge gap in lipotoxic cardiomyopathy 
studies. This study identified that miR-23a and miR-23b are highly sensitive to 
hyperlipidemia, and both are excellent candidates as initiating factors, which might fill a 
knowledge gap within the field.  
 
Histone Modifier in Response to High Fat Treatment 
Histone modifiers include histone methyltransferase, demethylases, acetyltransferases, 
deacetylases etc. The combination of those modifiers change the lysine residue on 
histone and affect gene transcription activity141. Limited studies have reported a close 
and systematic relationship between high fat diet and histone modifications in multiple 
46 
organs.  Currently, the relationship between histone modification and lipotoxic 
cardiomyopathy is largely unknown. Recent study by Sun et.al has indicated that high fat 
diet causes HDAC3 downregulation in hepatocytes that strongly induce expression of 
lipid-sequestering LDs-coating protein Perilipin 2 and leads to insulin hypersensitive and 
impaired glucose production, further causing severe hepatosteatosis and, notably 
increased insulin sensitivity without changes in body weight or insulin signaling 142. 
Another group has reported that 6-month-old male offspring from maternal high fat diet 
has a significant suppressed expression of Sirt-1 and HDAC1 in Hypothalamic Arcuate 
Nucleus that may contribute to hyperphagia and obesity in HF male offspring143. The 
third group found that excision of Hdac3 in heart and muscle later in development 
caused a severe hypertrophic cardiomyopathy and heart failure when adding on high fat 
diet for a few weeks, due to down-regulation of myocardial mitochondrial bioenergetic 
genes, specifically those involved in lipid metabolism144. In one recent cell culture study, 
palmitate treatment induced significant changes in H3 methylation in β cells145. Whether 
these histone modifications caused β cell dysfunction or the consequences of the β cell 
death resulted in epigenetic changes remains unknown145.  
None of the above 3 studies elucidate that how histone modifiers expression changes due 
to response to high fat treatment or their downstream targets that involved in the 
molecular mechanism of disease development in metabolism related organs or even 
cardiovascular system. It is of great interest and importance to understand the biology of 
histone modifier changes under high fat diet regulation and how histone modifiers 
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function as mediators in cardiovascular disease development in response to 
environmental stimuli. 
 
Materials and Methods 
 
Cell Culture and Palmitic Acid Treatment 
Human embryonic kidney epithelial cell line 293T (HEK 293T) was obtained from 
ATCC. Cells were cultured in DMEM with 10% FBS.  
 
Palmitic acid (P0500 Sigma Aldrich) was dissolved in DMSO and added into culture 
medium at final concentration 1µM. For the control group, the same amount of DMSO 
were added. 
 
Gene Transient Transfection 
All gene transient transfections were performed using the NEON transfection system 
(MPK5000; Life Technologies). 293T cells were suspended by the density of 5*10^7 
cells/ml, electroporation parameter was 1100 voltage, 20ms pulse width, 2 pulses, the 
efficiency of transfection is more than 80% under this condition.  
 
Cells were immediately seeded after the electroporation transfection. 
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High fat diet feeding and Palmitic Acid Treatment 
The Institutional Animal Care and Use Committee (IACUC) of Texas A&M University 
Health Science Center Institute of Biosciences and Technology approved the 
experiments with animals.  
 
Male mice with C57BL/6 background, at the age of 10 weeks, are fed with high fat diet 
(fat provide 60% Kcal, Research Diet, D12492). After feeding for 2 weeks, 
echocardiography was performed to record the cardiac function. 
 
Cardiac Function Assessment by Echocardiography 
For cardiovascular measurements, a Vevo770 High-Resolution Micro-Imaging System 
(Visual Sonics, Toronto, ON, Canada) with 30-MHz probe (RMV-707B) was used. 
 
 Male mice in each group, were anesthetized with 3–4% isoflurane, and then switched to 
1–1.5% isoflurane mixed with 100% oxygen. At the level of the papillary muscles, 2-
dimensional guided M-mode echocardiography was obtained from anterior (+septum) 
and posterior walls.  
 
Generation of Cardiac Muscle-Specific Setd2 Knockout Mice and Setd2 
Overexpression Transgenic Mouse Lines 
To avoid the constitutive Setd2 knockout result in early embryonic lethality, Setd2flox/flox 
mice were bred with α-MHC-Cre mice to generate Setd2f/f, α-MHC-Cre mice, respectively. 
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Human c-terminal Setd2 cDNA was subcloned into the α-myosin heavy chain (α-MHC) 
promoter expression vector for pronuclear microinjection with a C57/B6 background. 
Genomic DNA isolated from the tails of the mice was used for genotyping purposes. All 
animal experiments were approved by the Institutional Animal Care and Use Committee 
of the Texas A&M University Health Science Center-Houston. 
Chromatin Immunoprecipitation (ChIP) Assay 
To define the interaction of Setd2 with its histone dependent targets in vivo in the 
development of cardiac hypertrophy, a ChIP assay was performed. 
Hearts from 10- week-old Setd2f/f, α-MHC-Cre  and Setd2f/f mice were digested into single 
cardiomyocyte suspension and fixed with formaldehyde and lysed by sonication. 
 The specific Histone3 lysine36 tri-methylation antibody anti-H3K36me3(Abcam, ab-
9050, Cambridge, MA) was used to pull down-DNA fragment. 
Transverse Aortic Constriction 
Mice that have been fed with 2 weeks of high fat diet (60% KCal) or normal chow are 
anesthetized with 3% isoflurane with 100% oxygen. The thymus was retracted to expose 
the transverse aorta. Between the right innominate and left carotid artery, an aortic 
constriction was achieved by tying a 6-0 suture against a 3 mm length of 27 gauge 
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needle. After two knots, the 27 gauge needle was promptly removed, which yielded a 
constriction of ∼0.3 mm as the outer diameter of the 27 gauge needle. The procedure 
imposed a 60–80% aortic constriction on the animal. To minimize the variation of the 
constriction among the animals, only the mice with a ratio of right-to-left carotid artery 
flow velocity from 5 : 1 to 10 : 1 were used. The artery flow velocity was measured by a 
Pulsed Doppler (Indus Instruments, Houston, TX, USA). As a control, a sham operation 
without occlusion was performed on age-matched littermate mice. 
Hematoxylin and Eosin Staining, Immunostaining and Immunoblotting 
Mouse hearts were perfused and fixed by Langendorff Perfusion System (Radnoti, 
120108). The whole heart paraffin sections were applied to Hematoxylin and Eosin 
Staining (51275, Fluka; HT110132-1L, Sigma-Aldrich) and images were captured under 
1.25X magnify with Leica DM2000 histology microscope. 
Protein samples for Western blot analysis were extracted and separated as described 
previously146, and the immunoblotting densitometry was quantified by Gel Logic 6000 
PRO Imaging System (Carestream Health, Inc.). Antibodies were from the following 
sources: anti-setd2(Cell Signaling Technology,#23486, Danvers, MA), anti-
H3K36me3(Abcam, ab-9050, Cambridge, MA), anti-GAPDH (Santa Cruz, sc-20357, 
Dallas, TX), anti-β-actin(Santa Cruz, sc-8432, Dallas, TX), anti-lamin B1(Santa Cruz, 
sc-20682, Dallas ,TX).Equal protein loading was verified by the intensity of the GAPDH 
blot (Santa Cruz, sc-20357, TX, USA). 
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Paraffin sections of the whole heart were stained for wheat germ agglutinin (WGA) 
(Vector Laboratories, Burlingame, CA), pictures were taken under the 40x microscope 
objective. A total of 20 staining pictures from each group were quantified by Leica 
Application Suite Imaging Software (Version 4.0, Germany). Nuclei were visualized by 
DAPI staining. The images were acquired by fluorescence microscopy. 
 
Wheat Germ Agglutinin Staining and Quantification 
Paraffin sections of the whole heart were used for Wheat Germ Agglutinin (WGA) 
Staining. The tissue sessions were deparaffinized and incubated with Wheat Germ 
Agglutinin (Vector Laboratories, Burlingame, CA) at approximately 20 µg/ml in PBS to 
the sections and incubated for 30 minutes at room temperature. Washed with TPBS 
(PBS + 0.05% Tween™ 20) 3 times. Nuclei were visualized by 1 µg/ml DAPI staining 
for 5 min. Images were captured under the 40x microscope objective with Leica 
DM2000 histology microscope. One image was from the top of the interventricular 
septum and four images were from the left ventricle wall. A total of 20 staining pictures 
from each mouse were quantified by Leica Application Suite Imaging Software (Version 
4.0, Germany), single cardiomyocyte size was calculated based on a cross-section area 
marked by the staining.   
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RNA Sequencing Assay 
Total RNA was isolated from the hearts of 10-week-old mice using miRNeasy kit 
(QIAGEN, Cat No./ID: 217004), and 3µg was used for RNA-seq. The assessment was 
performed using the Qiagen RT2 Profile PCR Array. 
Data analyses were performed with R (www.r-project.org), a publicly available 
statistical tool for data analysis. Signaling pathway analysis was performed with 
Ingenuity (www.ingenuity.com). 
Dual-Luciferase Activity Assay for Measurement of Setd2 3’-UTR Activity 
Dual-luciferase assay was performed as described in our earlier study147, the 1kb region 
of Setd2 3’UTR was subcloned into a pGL3-basic vector expressing the luciferase 
reporter gene (Promega, Madison, WI, USA).  A similar vector with the miR-23a and 
miR-23b binding site mutant was constructed as a mutant reporter.  293-T cells were 
seeded in triplicates in a 12-well plate after transit transfection using Neon system. The 
cells in each group were then transfected with 1 ug of Setd2 3’-UTR firefly reporter 
plasmid and 20 ng of Renilla reporter plasmid together with 1ug of miR-23 expression 
vector or control vector. The cells were harvested 24 hour later. Dual-luciferase 
activities were measured using the Dual-Luciferase Reporter Assay System (Promega). 
The Renilla luciferase activity and the protein concentration were used for the 
normalization purpose. 
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RNA Isolation and qRT-PCR (Quantitative Polymerase Chain Reaction) Analysis 
Isolation of total RNA from mouse heart was performed using TRIzol reagent (Life 
Technologies). cDNAs were synthesized from 1 μg total RNA with the qScript One-Step 
RT-qPCR kit (Quanta Biosciences).  Quantitative RT-PCR was performed using SYBR 
Green PCR Master Mix (Life Technologies) in the StepOnePlus Real-Time PCR System 
according to the manufacturer’s instructions.  
Transcripts were quantified by quantitative PCR (qPCR) analysis. Total RNA was 
prepared by miRNeasy kit (QIAGEN, Cat No./ID: 217004); 0.5ug RNA was used for 
reverse transcription(QUANTA, 95048).  
 
The forward and reverse PCR primers (5′ to 3′) were as follows:  
Setd2 (mouse): TACTTGGGAAAGCCCAGGAG/ GCTTTTCTTTGCCAGCTCAC,  
Setd2 (human): AACTGGTTCCTTCAGGCTCA/ CTTCATTTTCCCTCCTGCTG, 
GAPDH (mouse): GAGTCAACGGATTTGGTCGT/TTGATTTTGGAGGGATCTCG, 
GAPDH(human): CATGGCCTTCCGTGTTCCTA/CCTGCTTCACCACCTTCTTGAT, 
GAPDH expression levels were used for qPCR normalization.  
Expression levels were determined by the 2−ΔΔCt threshold cycle method. 
 
Statistical analysis  
Data are presented as means ± s.d. Unpaired, two-tailed student’s t test was used for two 
group comparisons.  
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One-way ANOVA followed by Student-Newman-Keuls test was used for multiple group 
comparisons. 
All statistical analyses were performed in software SigmaPlot 11.0 (Systat, San Jose, CA, 
USA). The P value < 0.05 was considered as significant difference. 
Results of This Part 
Setd2 is Downregulated in High Fat Diet Fed Two Weeks Mouse Heart 
Non-bias RNA–sequencing data provide preliminary evidence that after 2-week high fat 
diet, over 100 gene expression change in mouse heart. With bioinformatic analysis to 
narrow down targets, in those genes, Setd2, which encoded histone methyltransferase 
that specific targets at tri-methylate histone lysine 36, was the only histone modifier that 
significantly downregulated.  Further verification by quantitative-PCR and 
immunoblotting, indicated that Setd2 in hearts of mice that fed with high fat diet for 2 
weeks decreased to 40% compared with mice that fed with normal diet (Fig.8). 
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Figure. 8. Short-term (2-week) HFD is a detrimental factor that exacerbates cardiac 
dysfunction and hypertrophy by downregulation of Setd2. (A). QPCR shows a 
significant decrease in Set2 transcript in 2-week HFD heart which further verified RNA-
Sequencing data. (B). An attenuated Set2 and H3K36me3 level is detected in HFD fed 2 
weeks mouse heart by Western blot.  * P<0.05, n=5. 
 
 
miR-23a and miR-23b Negatively Regulate Setd2 
With bioinformatic analysis, miR-23a and miR-23b have both been found to target at the 
3’-UTR of SET domain containing 2 (Setd2), a Histone 3 lysine 36 tri-methyltransferase 
with the most significant change in RNA-sequencing result. And the binding site for 
these 2 miRs on Setd2 3’UTR is highly conserved across species (Fig.9a). Luciferase 
activity assay shows that forced expression of miR-23a and miR-23b can repress the 
luciferase activity of vector that containing Setd2 3’UTR, while when the binding site is 
mutated, the repression effect caused by miR-23a and miR-23b is blunted (Fig.9b).  
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To determine whether miR-23a and miR-23b could silence Setd2 expression, forced 
expression of miR-23a, miR-23b or both of the miRs in 293T cell were achieved. Setd2 
mRNA was repressed 89% by miR-23a and 85% by miR-23b, 92% by miR-23a and 23b 
together (Fig.10a). Western blot from the cohort cell lysis shows the same trend. While 
antagomiR can reverse the trend as shown (Fig.10b), which further verified that Setd2 is 
directly negatively regulated by miR-23a and miR-23b. 
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Figure. 9. miR-23 bind Setd2 3’UTR and repress its expression. (A). Prediction of one  
putative targeting site (red) of miR-23 in the 3’-UTR of Setd2, and the comparison of 
targeting site sequence among different species. (B). miR-23a and miR-23b represses 
Setd2 3’-UTR reporter gene luciferase activity.  Mutation of miR-23 putative target site 
blocks the repressive effect of miR-23 on the target. * P<0.05.  
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Figure. 10. miR-23 repress Setd2 expression in vitro. (A). Forced expression of miR-23 
in 293 T cell by transit transfection represses Setd2 in both mRNA level and protein 
level, and its downstream target H3K36me3, as well. (B). Blunt miR-23 is achieved by 
antagomiR, and re-boost Setd2 expression and H3K36me3 separately and 
synergistically. * P<0.05, n=5. 
Setd2 Downregulation is Responsible for the Predisposed Cardiac Hypertrophy Induced 
by TAC in High Fat Diet Fed Mice 
Based on the in vitro results, our group tried to investigate whether high fat induced 
cardiac lipotoxicity by repressing Setd2 through miR-23a and miR-23b upregulation in 
mouse model. In the cohort heart that been injected with AAV DJ/8:miR-23a or AAV 
DJ/8:miR-23b, or both, Setd2 mRNA level was found repressed in high fat diet fed 2 
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weeks mice heart (Fig 11a). Setd2 and its downstream target H3K36me3 protein level 
were significantly downregulated after 2 weeks of injection (Fig 11b).  In contrast, 
antagomiR partially blunted miR-23’s repression on Setd2 and its downstream target 
H3K36me3 in mouse heart after 2 weeks of injection. (Fig.11 c&d). 
 60 
 
 
 
 
 
Figure. 11. miR-23 represses Setd2 expression in vivo (A). Overexpression of miR-23 in 
mouse cardiomyocyte archived by adeno-associate virus repress Setd2 expression level. 
(B). Attenuated Set2 and H3K36me3 expression by forced expression of miR-23 
separately or synergistically in cardiomyocyte. (C&D). AntagomiR treatment for reboost 
Setd2 mRNA and protein level and H3K36me3 in mouse heart. * P<0.05, n=5 
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Setd2 Knockout Indicate Multiple Cardiac Diseases Related Genes Expression 
Alteration   
Further correlation between loss of Setd2 and cardiac hypertrophy was indicated by a 
deep sequencing result performed on Setd2 cardiac specific knockout (MHC-Setd2-/-) 
mouse heart. RNA-seq shows multiple sets of genes with significant expression changes 
are related to cardiac hypertrophy, such as growth factor activity and binding; anion 
channel activity, heart contraction, hypoxia adaption, etc.. Deep sequencing data prove 
the concept that loss of Setd2 is strongly related to cardiac hypertrophy and provides 
further study direction (Fig.12.). 
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Figure. 12.  Cardiac disease-related gene expression profile in Setd2 knockout heart. (A). Top 50 genes with statically significant changes. (B). Genes related to growth factor activity.  (C). Genes related to heart 
contraction and anion channel activity.  (D). Genes related to hypoxia adaption and growth factor binding.  
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Setd2F/+, α-MHC-Cre Mice are Predisposed to TAC; Setd2 Cardiac Specific Transgenic 
Mice Partially Rescue the Cardiac Hypertrophy in Response to High Fat Diet and TAC  
To explore the biological significance of the downregulation of Setd2 by miR-23a and 
miR-23b and the consequence of decreased H3K36 tri-methylation in the high fat diet 
fed heart, genetic-loss and –gain of Setd2 mouse lines were generated, the cardiac-
specific Setd2-haploinsufficient (MHC-Setd2+/-) mice (Fig.13), and the cardiac-specific 
Setd2 overexpression transgenic(Tg-MHC-Setd2) mice (Fig.14). By taking advantage of 
these genetic Setd2 mouse models, cardiac-specific Setd2-haploinsufficient (MHC-
Setd2+/-) mice  that mimic the Setd2 downregulation in mouse heart after fed with high 
fat diet for 2 weeks, 3 weeks of TAC can induce severe cardiac dysfunction and 
hypertrophy in MHC-Setd2+/- mice compared with wild type littlemates (Fig.13) . 
While the cardiac-specific Setd2 overexpression can partially rescue the phenotype, 
shown as preserved cardiac function and less severe cardiac hypertrophy (Fig.14). 
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Figure. 13. Setd2F/+, a-MHC-cre mice are predisposed to TAC.  (A). Generation of cardiac-
specific Setd2 knockdown mice. (B). Setd2 mRNA level was quantified by qPCR, 
normalized with GAPDH. (C). Setd2 protein level was verified. The decreased 
H3K36me3 level is detected in the Setd2 haploinsufficient heart by immunoblot.  (D). 
Setd2F/+, a-MHC-cre mice are predisposed to TAC and developed dilated cardiomyopathy. 
(G). Echocardiography showing Setd2F/+, a-MHC-cre mice has a larger decrease in cardiac 
function than its control, and developed heart failure by the end of 3 weeks of TAC.. * 
P<0.05. n=5 
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Figure. 14. Setd2 cardiac-specific transgenic mice (Setd2-TG) partially rescue cardiac 
hypertrophy and heart failure in response to high fat diet and TAC   (A). Generation of 
Setd2 cardiac-specific overexpression mice; the inserted sequence was detected by PCR. 
(B). Setd2 overexpression was verified by immunoblot, and its downstream target 
H3K36me3 as well.  Setd2-TG mice are predisposed to TAC and developed dilated 
cardiomyopathy. (C). Forced Setd2 overexpression in cardiomyocyte can partially rescue 
the development of dilated cardiomyopathy after high fat diet and 3 week of TAC. (D). 
Setd2-TG mice showed preserved cardiac function when challenged with high fat diet 
followed by TAC. * P<0.05. 
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Discussion of This Part 
Histone Modification in Lipotoxic Cardiomyopathy 
Histone modification is an essential part of epigenetic regulation. Methylation and 
acetylation of lysine residues in the amino termini of histones 3 and 4 (H3 and H4, 
respectively) are typical examples of histone modifications, by which genetic 
accessibility can be altered in response to environmental stimuli. 
Currently, the relationship between histone modification and lipotoxic 
cardiomyopathy is largely unknown. In one recent cell culture study, palmitate 
treatment induced significant changes in H3 methylation in β cells145. However, whether 
these histone modifications caused β cells dysfunction or the consequences of the β cell 
death resulted in the epigenetic changes remains unknown145.  
Furthermore, a number of important questions remain unanswered: what is the signature 
pattern of HFD-induced histone modifications; and whether the changes of the histone 
modifications contribute to myocardial lipotoxicity. 
Our preliminary data showed a 64% decrease in Setd2 transcripts in the 2-week HFD 
mouse hearts compared to normal controls. The tri-methylation level of histone 3 lysine 
36 (H3K36me3) was reduced significantly. Further evidence has linked the responsive 
upregulation of miR-23a and miR-23b in early exposure to high fat diet with repressed 
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Setd2 expression both in vivo and in vitro. The above preliminary study drives the 
hypothesis short-term(2 weeks) administration of high fat diet in mouse will not cause 
any metabolism change, while predisposed miR-23a and miR-23b elevation in heart,  
which leads to predisposed to cardiac hypertrophy even heart failure after hemodynamic 
stress due to the loss of a histone methyltransferase Setd2. 
 
 From the data of RNA-Seq and miR-Seq results, among hundreds of upregulated genes 
and miRNAs, with the help of bioinformatic analysis to match miRNAs and their 
potential targets, two miRNAs and a histone methyltransferase stand out. It is well 
known that miRNAs function as gene repressors by binding to the 3’UTR of a target 
gene and block its translation, or directly degrade the mRNA. By applying the 
bioinformatic system of Target Scan, it has been revealed that on the 3’-UTR of Setd2 
exist a common binding site of miR-23a-3p and miR-23b-3p. It is well known that 
microRNA has multiple targets and a specific gene can be regulated by different 
microRNAs. To further investigate the relationship between the 2 miRs and Setd2, a 
luciferase vector contaiing Setd2 3’UTR was built to indicate that miR-23a and miR-23b 
can bind to Setd2 3’UTR and repress the luciferase activity and mutation of the binding 
site that can fully blunt the repression of miR-23a-3p and miR-23b-3p. Even this project 
has provide solid evidence that miR-23a and miR-23b negatively regulate Setd2 through 
its 3’UTR during early exposure to high fat diet, the RNA-Seq and miR-Seq data can 
provided further subjects for future studies. 
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We propose a working model in this study and provide evidence indicating that miR- 
23a and miR-23b are “lipid sensors”. High fat diet induced the upregulation on these 2 
micro RNA in the heart, and function as antagonists to histone methyltransferase Setd2 
through binding to Setd2 3’UTR and repress the transcription and translation of this 
histone modifier, Setd2 downregulation caused the cardiac hypertrophy signal cascade, 
further leads to heart predispose to hemodynamic stress. This is the first study in which 
miR-23a and miR-23b functions as upstream sensors that conduct epigenetic regulation 
of the development of lipotoxic cardiomyopathy in prediabetes. The process is 
dynamically regulated, down-regulation of Setd2 reduces the tri-methylation of Histone 
3 lysine 36, the latter promotes a cascade of signaling pathways changes which are 
highly involved in cardiovascular diseases. 
Role of Setd2 in Cardiac Hypertrophy 
The pathological functions of Setd2 have been largely associated with clear renal 
cell carcinoma as a tumor suppressor148, 149. Genetic global silencing of Setd2 in 
mice was embryonically lethal with compromised vascular development150. Recent 
emerging evidence indicates that Setd2 also participates in inhibiting liver cancer 
stem cell proliferation151 in which Setd2 function is consistent with our results 
through different mechanisms. We recently reported that Setd2 was essential for 
skeletal muscle cell proliferation and differentiation. Genetic silencing of Setd2 
abolished myotube formation and inhibited muscle cell growth by repressing 
myogenein transcriptional activity and activating cyclin-dependent kinase inhibitor 
69 
p21152. The Setd2 deficiency-medicated proliferative effect is in line with our 
finding in cardiomyocyte. It is important to note that the basic knowledge of Setd2 
in a normal heart and in a lipid-induced pathological situation remains unknown, 
 To explore the biological significance of the downregulation of Setd2 and the 
consequence of decreased H3K36 tri-methylation in the heart, we generated genetic loss- 
and -gain-of-function mouse lines: the cardiac-specific Setd2-haploinsufficient (MHC-
Setd2+/-) and the cardiac-specific Setd2 overexpression transgenic mice (Tg-MHC-
Setd2). The Setd2 heterozygous mice, which mimic high fat diet induced Setd2 
repression in the heart, exhibited normal cardiac contractile function under physiological 
conditions. While they are predisposed hemodynamic challenge with dilated 
cardiomyopathy, demonstrate that the decreased level of H3K36 tri-methylation is 
detrimental for normal cardiac function, which triggers a cascade of harmful gene 
activation, leading to HFD-induced cardiac toxicity. 
 The RNA-seq has provided multiple pathways that can be involved in heart contraction, 
anion channel activity growth factor activity and binding; all might contribute to the 
dilated cardiac hypertrophy caused by high fat diet plus hemodynamic stress. The 
chromatin immunoprecipitation (ChIP) sequencing will provide evidence of the genes 
that have been regulated by histone 3 lysine 36 methylation in Setd2 cardiac specific 
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knockout mice, which further indicated that cardiac hypertrophy related genes are 
positively regulated with early exposure to high fat diet due to loss of Setd2. 
As noted above, 2-week of high fat diet contributes to predispose to hemodynamic 
challenge in mouse heart; it is difficult to separate the effects of pure high fat from 
glucose increase in the present investigation. A link between the high circulation 
glucose and cardiac hypertrophy was suggested in the 1980s and 1990s153, 154, 
while the relationship between early high fat diet and cardiovascular susceptibility 
to stress has not been addressed in previous studies. Our group also did a parallel 
experiment by feeding the mice fructose water for 2 weeks, then performed TAC 
on them. Three week after TAC, cardiac function was significantly dropped with 
Setd2 repression, while there was no significant change of miR-23a and miR-23b. 
This pilot experiment indicated that loss of Setd2 leads to higher susceptibility to 
stress and cardiac hypertrophy, even heart failure. Future study should be focus on 
investigating Setd2 downregulation mediated cardiac hypertrophy, as well as miR-
23a and miR-23b function as lipid sensors mediated on other metabolism-related 
signaling pathways. 
It is important to note that this study does have limit due to the study model and 
the cell treatment that has been applied. Animals are under high fat diet for only 2 
weeks which extended the individual variation in response to high fat diet and later 
the hemodynamic stress (TAC), this limit can be compensated for by expansion of 
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the sample size. In vitro, this study used palmitic acid to mimic the high fat diet 
condition in cell culture, which is a saturated fatty acid. There are other studies that 
apply linoleic acid or other unsaturated fatty acid, that or a mixture of saturated 
and unsaturated fatty acid to cardiomyocyte. The unsaturated fatty acids were 
reported to have an unignorably cardiac protective function in high glycose treated 
cardiomyocyte155. In addition to the current study, the responsive upregulation of 
miR-23a and miR-23b to other fatty acid treatment should be investigated as well. 
Also, it is still unknown that how a high fat diet environment triggers the 
upregulation of these 2 miRs, which could lead to further investigations. 
In summary, this study demonstrates an essential role of epigenetic regulation in 
the development of lipotoxic cardiomyopathy during early high fat diet exposure. 
Upregulation of miR-23a and miR-23b predisposes the animal hearts to transition 
to dilated cardiomyopathy and heart failure through repressed Setd2 expression. 
Blocking of Setd2 function is partially responsible for this maladaptive transition. 
Inhibition of miR23a and miR23b is sufficient to rescue the Setd2-mediated 
cardiac hypertrophy in the high fat diet fed animals even after TAC. Genetically 
forced overexpression of Setd2 in cardiomyocyte or blocking miR-23a and miR-
23b by applying antagomiR will rescue the dilated cardiomyopathy phenotype. 
The finding of miR-23a and miR-23b effects on Setd2, and Setd2 inhibition caused 
cardiac hypertrophy shed light on a new concept of epigenetic regulation in the 
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development of cardiac lipotoxicity in prediabetes caused by high fat diet. Given 
the novel “lipid sensor” role of miR-23a and miR2-3b and their inhibition on 
Setd2-caused cardiomyopathy, our findings provide a potential alternative target 
for pharmacological manipulation in lipotoxic cardiomyopathy prevention.  
 
 
Figure. 15. Molecular mechanism of lipotoxic cardiomyopathy. Short-term 
excessive fatty acid exposure upregulates miR-23a and miR-23b expression, which 
in turn represses Setd2 expression. The downregulation of Setd2 leads to lipotoxic 
cardiomyopathy. 
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CHAPTER IV
CONCLUSION 
The epigenetic signaling mechanism leading to excessive lipid-induced cardiac 
complication before obesity, coronary atherosclerosis or obesity-associated metabolic 
syndromes is yet to be accomplished. While in this study, I found one of the epigenetic 
regulatory pathway that involved in lipid-overload induced cardiomyopathy in the early 
exposure. And this is the first time to show that histone methyltransferase setd2 can be 
repressed by microRNA-23a and 23b and further leads to cardiomyopathy. 
The innovation of this study can be concluded as: 
1) miR-23a and miR-23b are identified as lipid overload sensors;
2) Upregulation of miR-23a and/or miR-23b is linked to lipotoxic cardiomyopathy;
3) Discovery of Setd2 as a downstream target of miR-23a and miR-23b;
4) Setd2 is obligatory for normal cardiac function;
5) Downregulation of Setd2 is responsible for miR-23a and miR-23b-mediated lipotoxic
cardiomyopathy. 
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